Israel - hebreu - Ministry of Health

pfizer pharmaceuticals israel ltd - inotuzumab ozogamicin - אבקה להכנת תמיסה מרוכזת לעירוי - inotuzumab ozogamicin 1 mg/vial - inotuzumab ozogamicin

Israel - hebreu - Ministry of Health

pfizer pharmaceuticals israel ltd - pegvisomant - אבקה וממס להכנת תמיסה להזרקה - pegvisomant 25 mg/vial - pegvisomant

Israel - hebreu - Ministry of Health

pfizer pharmaceuticals israel ltd - pegvisomant - אבקה וממס להכנת תמיסה להזרקה - pegvisomant 30 mg/vial - pegvisomant

Israel - hebreu - Ministry of Health

pfizer pharmaceuticals israel ltd - sunitinib as malate - קפסולות - sunitinib as malate 12.5 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

Israel - hebreu - Ministry of Health

pfizer pharmaceuticals israel ltd - sunitinib as malate - קפסולות - sunitinib as malate 25 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

Israel - hebreu - Ministry of Health

pfizer pharmaceuticals israel ltd - sunitinib as malate - קפסולות - sunitinib as malate 50 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

Israel - hebreu - Ministry of Health

pfizer pharmaceuticals israel ltd - tigecycline - אבקה מיובשת בהקפאה לאינפוזיה - tigecycline 50 mg/dose - tigecycline - tigecycline - tygacil is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below for patients 18 years of age and older:complicated skin and skin structure infections:complicated skin and skin structure infections caused by escherichia coli, enterococcus faecalis (vancomycin-susceptible isolates ), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus agalactiae, streptococcus anginosus grp. (includes s. anginosus, s. intermedius, and s. constellatus), streptococcus pyogenes, enterobacter cloacae, klebsiella pneumoniae, and bacteroides fragilis .complicated intra-abdominal infections:complicated intra-abdominal infections caused by citrobacter freundii, enterobacter cloacae, escherichia coli, klebsiella oxytoca, klebsiella pneumoniae, enterococcus faecalis (vancomycin-susceptible isolates), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus anginosus grp. (includes s. anginosu

Israel - hebreu - Ministry of Health

pfizer pharmaceuticals israel ltd - varenicline as tartrate - טבליות מצופות פילם - varenicline as tartrate 0.5 mg - varenicline - varenicline - champix is indicated as an aid to smoking cessation treatment adults over 18 years of age.

Israel - hebreu - Ministry of Health

pfizer pharmaceuticals israel ltd - varenicline as tartrate - טבליות מצופות פילם - varenicline as tartrate 1 mg - varenicline - varenicline - champix is indicated as an aid to smoking cessation treatment adults over 18 years of age.

Israel - hebreu - Ministry of Health

pfizer pharmaceuticals israel ltd - somatropin - אבקה להכנת תמיסה לזריקה - somatropin 5.3 mg - somatropin - somatropin - children: short stature due to inadequate or failed secretion of pituitary growth hormone or turner`s syndrome. short stature in children with renal insufficiency. growth disturbance (height sds<2.5 and parenteral adjusted height sds < -1) in short children born sga (sga - small for gestational age i.e. born small in relation to the length of the fetus development) with a birth weight and/or length < 2 sd who failed to show catch up growth (hv sds < 0 during the last year) by 4 years of age or later. prader willi syndrome for improvement of growth and body composition. adults: for adults who have suffered from growth-hormone deficiency since childhood. for adults who have aquired growth hormone deficiency due to a pituitary pathology causing hypopituitarism.